Spero Therapeutics Inc. (SPRO)
NASDAQ: SPROHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
SPRO stock chart
Technical analysisKey statistics
All statistics- Market cap
- $43.23M
- EPS (TTM)
- -$0.50
- Dividend yield
- None
- 52-week range
- 0.73 – 3.08
- Day range
- 0.7301 – 0.81
- Volume / Avg
- 424.81K / 530.46K
- Beta
- —
- Shares outstanding
- 58.26M
52-week range
SPRO stock today
Shares of Spero Therapeutics (SPRO) finished lower on Nov 20 at $0.742, a drop of 10.20% or $0.0843 per share, versus the S&P 500's 3.70% decline. At this level, SPRO sits near the bottom of its 52-week range of $0.73 to $3.08: 75.9% below the high, set on May 27, 2026 and 1.6% above the low. SPRO is down 68.2% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 67.9%.
Spero Therapeutics has posted a net loss over the last twelve months (EPS of -$0.50), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Spero Therapeutics
Company profileSpero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adult patients, which has completed second Phase 3 trial. It has license agreement with Meiji Seika Pharma Co., Ltd.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Ms. Esther P. Rajavelu
- Headquarters
- Cambridge, MA
- Employees
- 25
- IPO year
- 2017
- Website
- sperotherapeutics.com
Financial highlights
Full financialsIn fiscal 2025, Spero Therapeutics generated $66.8 million in revenue, up 39.2% from fiscal 2024. Net income was $8.6 million, for a net margin of 12.8% versus a median of -142.9% in the prior 5 years. Operating margin was 9.5%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $66.80M | $47.98M | $103.78M | $53.51M | $18.26M |
| Growth | +39.24% | -53.77% | +93.95% | +193.10% | +95.67% |
| Net income | $8.57M | $-68.57M | $22.81M | $-46.41M | $-89.80M |
| EPS (diluted) | $0.15 | $-1.27 | $0.43 | $-1.23 | $-2.91 |
Analyst forecast
ForecastConsensus (2 analysts)
none
Avg. price target
$5.00+573.85%
- Strong buy 0
- Buy 1
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 12, 2026
- EPS actual vs est.
- $-0.76 vs $-0.14
- Surprise
- -442.86%
SPRO news
All SPRO news- Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Spero Therapeutics to Present at Investor Conferences in NovemberGlobeNewswire
- Cantor Fitzgerald Initiates Coverage of Spero Therapeutics at OverweightNasdaq
- Spero Therapeutics, Inc. Announces Retirement of Chief Operating Officer Timothy KeutzerNasdaqSPRO, DDS
- Spero Therapeutics Strengthens Leadership Team to Advance Immunology PipelineGlobeNewswire
- Spero Therapeutics to Participate in the Chardan 10th Annual Healthcare ConferenceGlobeNewswire
Spero Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| RLYBRallybio Corporation | 15.47 | -0.32% | $43.32M | vs SPRO |
| CRBPCorbus Pharmaceuticals Holdings Inc. | 2.06 | -15.40% | $42.45M | vs SPRO |
| ANVSAnnovis Bio Inc. | 0.7113 | -4.96% | $44.12M | vs SPRO |
| INCRIntercure Ltd. | 3.24 | -7.69% | $42.03M | vs SPRO |
| OSTXOS Therapies Incorporated | 0.803 | -2.12% | $42.00M | vs SPRO |
| GANXGain Therapeutics Inc. | 0.9994 | -4.82% | $44.50M | vs SPRO |
| QUCYQuantum Cyber N.V. | 0.512 | -7.25% | $44.67M | vs SPRO |
| BMEABiomea Fusion Inc. | 0.5744 | -2.38% | $41.75M | vs SPRO |
Indexes, lists and sector
Spero Therapeutics stock FAQ
What is Spero Therapeutics's stock price today?
SPRO last traded at $0.742 as of Nov 20, 4:00 PM EST, down 10.20% on the day. Prices are delayed at least 15 minutes.
Who is Spero Therapeutics's CEO?
Ms. Esther P. Rajavelu is the chief executive officer of Spero Therapeutics Inc., which has about 25 employees.
What is the SPRO 52-week high?
The 52-week high for SPRO is $3.08 and the 52-week low is $0.73. The stock is currently 75.9% below its high.